TAK1 mediates the collagen-II-dependent induction of the COX-2 gene and PGE2 release in primary human chondrocytes

• Published in: Connective tissue research 2010-12, Vol.51 (6), p.452-458
• Main Authors: Klatt, Andreas R., Klinger, Gabriele, Paul-Klausch, Brigitte, Renno, Joerg H., Schmidt, Joachim, Malchau, Gebhart, Wielckens, Klaus
• Format: Article
• Language: English
• Subjects: Cartilage, Articular - cytology; Cartilage, Articular - metabolism; Cartilage, Articular - pathology; Cells, Cultured; Chondrocytes - enzymology; Chondrocytes - secretion; collagen II; Collagen Type II - physiology; COX-2; Cyclooxygenase 2 - biosynthesis; Cyclooxygenase 2 - genetics; Dinoprostone - metabolism; Dinoprostone - secretion; Gene Expression Regulation - physiology; Gene Silencing - physiology; Humans; MAP Kinase Kinase Kinases - physiology; osteoarthritis; Osteoarthritis - genetics; Osteoarthritis - metabolism; Osteoarthritis - pathology; PHC; TAK1
• ISSN: 0300-8207; 1607-8438
• DOI: 10.3109/03008201003668360

We investigated the role of transforming growth factor-beta activated kinase 1 (TAK1) in collagen II signaling in primary human chondrocytes (PHCs). We asked whether TAK1 acts as a modulator of collagen II signaling with respect to collagen-II-dependent induction of cyclooxigenase-2 (COX-2) in PHCs and release of PGE2 from PHCs. Therefore, PHCs were incubated with collagen II, and cells were then analyzed by RT-PCR for the expression of COX-2. ELISA was used to quantify PGE2 release. To examine the influence of TAK1 on these events, TAK1 gene silencing was performed by RNAi in PHCs prior to collagen II treatment. Results indicated that COX-2 gene expression and PGE2 release are specific outcomes of collagen II signaling and that both depend on TAK1 mediation. These findings are promising in that therapeutic inhibition of TAK1 might be used to reduce pain and relieve inflammatory symptoms that are common in osteoarthritis.